N4 Pharma Plc

Nigel Theobald

Newsletter

Default features description for sign up page.

Why Invest

Case studies

Why Invest (Navigation)

Senior leadership team

Nanogenics

Leadership team

About Us

Company

N4 101

ECP 105

Partnership opportunities

SRI Collaboration

Pipeline & partnerships

Nuvec®

Regulatory news

Media

In the news

Contact us

Presentations

Investors Home

AIM Rule 26

N4 Pharma Education

Investors

Home

Open Sans

Dear loyal shareholders, interested investors and partners,

Welcome to The N4 Notebook – N4 Pharma’s new home for insights, updates, and progress. This is where we’ll share the thinking behind our pipeline, explore the science that drives our work, and keep investors and followers in the loop on what’s next. 

Whether it's progress in the lab, reflections from our leadership team, or developments across the RNA therapeutics landscape, this blog is designed to offer a deeper look into the world of N4, beyond the RNS.

For our first post, we’re highlighting a recent series of short clips from Life Sciences Decoded, where our CEO Nigel Theobald talks all things RNA: why these medicines are so promising, what’s holding them back, and how Nuvec® is designed to help unlock their full potential. Whether you're new to RNA or following N4 closely, it’s a great starting point to better understand our platform and where we’re heading.

To close out this first edition of The n4 Notebook, I want to take a moment to thank those who continue to follow our journey.

Behind every RNS and research update is a small but incredibly dedicated team working to push boundaries in RNA delivery—one experiment, one innovation, one conversation at a time.

We look forward to sharing more insights, stories, and progress with you here as we continue to develop Nuvec® and our pipeline of novel RNA therapeutics.

As always, thank you for your continued interest and support.

View the videos and blog below and submit your questions